A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Conditions: Breast Cancer Interventions: Drug: 6.0 mg/kg of TQB2102 for injection; Drug: 7.5 mg/kg of TQB2102 for injection Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials